Concept to Commercialization: The Role of CDMOs in Driving Innovation Through Phase-Appropriate Technology Transfers

Concept to Commercialization: The Role of CDMOs in Driving Pharma Innovation Through Phase-Appropriate Technology Transfers

Brought to you by Veranova

Overview

Contract Development & Manufacturing Organizations (CDMOs) are crucial in driving innovation within the pharma industry. Companies are increasingly leveraging the expertise of CDMOs through technology transfers to foster innovation and accelerate the growth of new drugs.

Technology transfer is essential at various stages of drug development, from preclinical phases to commercialization. This white paper highlights the significance of CDMOs in advancing pharmaceutical development and discusses the benefits of collaboration for efficient, cost-effective and high-quality drug development processes.

Key Objectives:

What is a ‘technology transfer’ between originator and CDMO
The technology transfer cycle from preclinical to commercial stage
How to initiate the technology transfer process
How a CDMO can ensure continuous improvement in their technology transfer
Factors affecting a successful technology transfer

Brought to you by:

This content was created by Veranova, without editorial input from the C&EN Media Group. For more information on C&EN's custom products, visit our C&EN Media Kit.

Please complete the form to download the white paper.

Forwarded this link? Clear the form

Email Address*

Salutation*

First Name*

Last Name*

Company*

Job Title

Address 1*

City*

State*

Zip / Post Code*

Country*

Business Phone*

I would like to receive more information on products and services from the American Chemical Society

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.